Human fibrinogen/Human thrombin (Baxalta)

N/A

Report date: 2022/03/01 14:18:11

Base Information

Drug NameHuman fibrinogen/Human thrombin (Baxalta)
Drug Alias Name血液纤维蛋白粘合剂Sealer Protein (Human)/Thrombin (Human)人源血纤蛋白粘合剂Tisseel
ClassificationBiologics > Blood components
Mechanisms of ActionFibrinogen replacementsProthrombin replacements
TargetsProthrombinFibrinogen
Therapy Area/IndicationsHemorrhageEcchymosisBlepharoptosis +[5] 
Global Approved IndicationsHemorrhage
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1998/05/01
Country/TerritoryCzechiaUnited StatesRussian Federation +[5] 
CombinationsYes
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke UniversityUniversity Of CalgaryBaxter Healthcare Corp
Active IndicationsHemorrhage
Inactive IndicationsEcchymosisBlepharoptosisSeizures +[4] 

Other Information

ATC CodeB02BB01
Related LinksN/A